# US 2010/0166675 A1 · Pharmaceutical Composition for the Treatment of Type 1-Diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166675 A1
- Document ID: US20100166675A1
- Status: Published application
- Kind: A1
- Application number: 12/643,008
- Filed: 2009-12-21
- Published: 2010-07-01
- Earliest claimed: 2008-12-19
- Assignees: Qinghua Wang
- Inventors: Qinghua WANG; Soltani NEPTON
- Web page: https://patentgrep.com/patent/US20100166675A1

## CPC

- C07K 14/605: Glucagons
- A61K 31/195: having an amino group
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/2278: {Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1/Ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of T1D in mammals.

## Claims

### Claim 1

A method of treating type 1 diabetes (T1D), said method comprising administering to a subject having T1D a therapeutically effective amount of a composition comprising a GABAergic compound, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1 wherein the composition administered further comprises an effective amount of an incretin, selected from glucagon-like peptide-1 (GLP-1), exendin-4 (Ex4) or variants or derivates thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein said GABAergic compound is selected from GABA, or GABA precursor glutamate, GAD65, GAD67, a GABA receptor agonist, a type A GABA receptor (GABAAR) agonist, or GABA variants selected from a GABA chemical conjugant, GABA fusion or GABA with a chemically modified or replaced amino group, or derivates thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein said GABA fusion is selected from GABA-albumin fusion or GABA-IgGFc fusion; or wherein said GABA with a chemically modified or replaced amino group is selected from said amino group modified or replaced with a halogen group, an alkyl group, a cycloalkyl group, a methyl group, an alkoxy group, an aryl group, or a heteroaryl group.

### Claim 5 (depends on 2)

The method of claim 2, wherein said GLP-1 or variant thereof is selected from GLP-1(7-37)OH, GLP-1(7-36)amide-1, a DPPIV resistant GLP-1, a GLP-1 fusion protein, and fragments and derivatives thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein said DPPIV resistant GLP-1 is GLP-1A8X, wherein X is any amino acid other than A, optionally, GLP-1A8G, N-acetyl-GLP-1, N-methylated-(N-me-GLP-1), α-methylated (α-me-GLP-1), desamidated-(desamino-GLP-1) and imidazole-lactic-acid substituted GLP-1 (imi-GLP-1), or wherein the N-terminal modified GLP-1 such as by covalently linking GLP-1 to a fatty acid chain, or wherein the GLP-1 fusion protein comprises an IgG Fc or albumin.

### Claim 7 (depends on 2)

The method of claim 2, wherein said GABAergic and incretin are separate molecules, or are fused together to form a single GABAergic/incretin fusion polypeptide or nucleic acid encoding said polypeptide or variants or derivates thereof.

### Claim 8

A composition, comprising a GABAergic compound and an incretin and optionally a pharmaceutically suitable carrier.

### Claim 9 (depends on 8)

The composition of claim 8 wherein said incretin is selected from glucagon-like peptide-1 (GLP-1), exendin-4 (Ex4) or variants or derivates thereof and said GABAergic compound is selected from GABA, glutamate, GAD65, GAD67, a GABA receptor agonist, a type A GABA receptor (GABAAR) agonist, or GABA variants selected from a GABA chemical conjugant, GABA fusion or GABA with a chemically modified or replaced amino group, or derivates thereof.

### Claim 10 (depends on 9)

The composition of claim 9, wherein said GABA fusion is selected from GABA-albumin fusion or GABA-IgGFc fusion; or wherein said GABA with a chemically modified or replaced amino group is selected from said amino group modified or replaced with a halogen group, an alkyl group, a cycloalkyl group, a methyl group, an alkoxy group, an aryl group, or a heteroaryl group.

### Claim 11 (depends on 9)

The composition of claim 9, wherein said GLP-1 or variant thereof is selected from GLP-1(7-37)OH, GLP-1(7-36)amide-1, a DPPIV resistant GLP-1, a GLP-1 fusion protein, and fragments and derivatives thereof.

### Claim 12 (depends on 9)

The composition of claim 9, wherein said DPPIV resistant GLP-1 is GLP-1A8X, wherein X is any amino acid other than A, optionally, GLP-1A8G or wherein the GLP-1 fusion protein comprises an IgG Fc or albumin.

### Claim 13 (depends on 9)

The composition of claim 9, wherein said GLP-1 or Ex4 is a polypeptide variant, wherein said GLP-1 polypeptide variant comprises about 70% to about 99.9% sequence identity with GLP-1 of SEQ ID NO.1; or wherein said Ex4 polypeptide variant comprises a polypeptide from about 70% to about 99.9% sequence identity with Ex4 of SEQ ID NO.2.

### Claim 14 (depends on 8)

The composition of claim 8 comprising one or more polypeptides selected from SEQ ID NO:1-7, or comprising one or more nucleic acids encoding said polypeptides selected from SEQ ID NO:1-7.

### Claim 15 (depends on 1)

The method of claim 1, wherein said composition is administered by a method selected from topical administration, oral administration, aerosol administration, intraperitoneal injection, intravenous injection and/or intramuscular injection.

### Claim 16 (depends on 2)

The method of claim 2, wherein said GLP-1 or Ex4 is a polypeptide variant, wherein said GLP-1 polypeptide variant comprises about 70% to about 100% sequence identity with GLP-1 of SEQ ID NO.1; or wherein said Ex4 polypeptide variant comprises a polypeptide from about 70% to about 100% sequence identity with Ex4 of SEQ ID NO.2.

### Claim 17 (depends on 1)

The method of claim 1 wherein the composition administered comprises one or more polypeptides selected from SEQ ID NO:1-7, or comprising one or more nucleic acids encoding said polypeptides selected from SEQ ID NO:1-7.

### Claim 18 (depends on 1)

The method of claim 1 wherein one or more of the GABAergic compound or incretin in said composition is provided as a nucleic acid sequence, optionally comprised in a vector, wherein the vector is optionally a non-viral vector, a viral delivery vehicle, or for bacterial or mammalian expression.

### Claim 19 (depends on 1)

The method of claim 1, wherein the dosage of the composition is 0.01-10 mmol/kg of GABAergic compound and 0.02 to 1000 nmol/kg of incretin or between about 0.002-2 mg/kg of GABAergic compound and 0.2-1000 nmol/kg of incretin; wherein the GABAergic compound and incretin are preferably GABA and GLP-1 and/or Ex4 polypeptides.

### Claim 20 (depends on 1)

The method of claim 1, wherein the composition comprises nucleic acid DNA encoding the respective compound in composition for use may be about 1 μg/kg of body weight to 10 μg/kg of body or between 0.1 to 100 μg/kg of body weight. Suitable concentrations of the DNA vaccine for use comprise 0.1 to about 1000 microgram of DNA.
